CAMURUS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 473.6 SEK | -4.86% |
|
-7.05% | -11.97% |
| Apr. 17 | Certain Shares of Camurus AB are subject to a Lock-Up Agreement Ending on 17-APR-2024. | CI |
| Apr. 02 | Camurus AB Announces Board Resignations | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Companyâs products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
473.6
SEK
Average target price
577.2
SEK
Spread / Average Target
+21.87%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.97% | 2.61B | |
| +27.97% | 676B | |
| +23.58% | 554B | |
| -7.02% | 349B | |
| +14.85% | 318B | |
| +6.25% | 291B | |
| +2.96% | 210B | |
| -0.41% | 204B | |
| -10.02% | 194B | |
| -11.81% | 144B |
- Stock Market
- Equities
- CAMX Stock
- News Camurus AB
- Camurus : Appoints New CFO
